CGTX

Cognition Therapeutics, Inc. (CGTX) | Rumor.io

Cognition Therapeutics

CGTX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,579

Bullish sentiment (50-day avg)71%

Price to earnings ratio-2.95

Market capitalization89.2M

Earnings per share-0.17

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-23.5M

Social

What share of all stock conversation is about CGTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.01

Jun 25

$CGTX has dropped significantly, with some speculating that the market was expecting a partnership announcement, but the FDA is still in alignment.
The company's fundamentals remain intact, with the Phase 3 DLB trial essentially confirmed and the NDA path still intact, according to some analysts.
Some investors are holding onto their long positions, with one suggesting that a large ATM (Accelerated Trading Market) may be behind the drop, and another proposing that the CEO take most of her annual compensation in stock to demonstrate her confidence in the company.

Generated by AI

Sentiment

Of the messages about CGTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% new	58.33% -16.67	89.58% +0.74
Bearish	—	50% -50	41.67% +16.67	10.42% -0.74

Bullish· Apr 1

$CGTX has shown a significant 60% increase in value, making it a profitable long-term hold.
The asset's low float is expected to lead to a price explosion, with a predicted target of $1.20.
$CGTX has already shown a remarkable turnaround, with a strong possibility of breaking through the $1 mark and potentially reaching $3.

Bearish· Jun 24

The company may be diluting the stock by selling more shares, similar to a previous massive drop.
The market may be reacting to anticipation of negative news, with some expecting a possible drop despite positive news being "baked into the share price".
The company's recent price drop may be a buying opportunity, with some investors believing there's a 50/50 chance of a total loss over a long-term horizon.

Generated by AI

Topics

Of the messages about CGTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	53.09%
Technical Analysis	0%	0%	0%	39.3%
Earnings	0%	0%	0%	2.54%
Analysts	0%	0%	0%	3.33%
Controversies	0%	0%	0%	0.16%
Macro	0%	0%	0%	1.58%

Announcements· Aug 28

Cognition Therapeutics, Inc. (CGTX) has announced a $30 million registered direct offering of 14.7 million shares to two new institutional investors, including a major global investment manager.
The proceeds from the offering will be used to advance Phase 3 programs for zervimesine, a potential treatment for Alzheimer's disease.
The offering is expected to provide a bridge funding in preparation for Phase 3 trials and may also extend the company's runway through late 2026, potentially making a buyout more likely due to increased valuations.

Technical Analysis· Aug 25

$CGTX is expected to reach $5 soon, with a current price and only 73 million outstanding shares.
The stock is showing a cup and handle formation on the 5-minute chart and a beautiful stair-stepping and consolidation pattern.
$CGTX is oversold and due for a bounce, with a potential target at $3.80 and a current price near support at $3.27.

Generated by AI

Community

Of the messages about CGTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	96.15%	87.32%	72.46%
Newcomers	14.29%	3.85%	12.68%	27.54%

Regulars· Aug 22

CGTX is exhibiting strong momentum, holding VWAP and grinding higher into $2.65, with a steep uptrend that may continue as long as it holds.
The stock's price is being closely watched by regulars, with notable price points at $2.55, $3.01, and $3.70, and a support level at $2.13.
UltraShort and UltraBuyer signals have triggered sharp price movements, with UltraShorts sparking drops of up to 20% and UltraBuyers experiencing a 60% pop before the price stalled near resistance.

Newcomers· Aug 28

Newcomers are noting the significant price increase of CGTX, which has risen by 500% in 18 days.
Some newcomers are analyzing the potential for a "pop-and-hold" in CGTX, citing Phase 3 funding and a $30M deal as narrative support.
Others are looking at a possible "flush-and-reset" in CGTX, seeing the $30M offering as strengthening the company's runway for Phase 3, despite current weakness.

Generated by AI

PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company’s development of zervimesine for Alzheimer

22d agoYahoo Finance

Best Penny Stocks of 2026: Are They a Good Investment? | The Motley Fool

Looking to invest in penny stocks? See which affordable stocks are standing out and showing potential for growth.

1mo agoThe Motley Fool

H.C. Wainwright reiterates Cognition stock rating, $3 target

1mo agoInvesting.com

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

1mo agoYahoo Finance

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quarter marked important progress across both our clinical and corporate priorities,” said Lisa Ricciardi, Cognition’s president and CEO. “Discussions with th

1mo agoYahoo Finance

Also Discussed

Investors talking about CGTX also mention

#	Name	Attention
1	Incannex Healthcare Inc.IXHL	0.01%0
2	Tharimmune Inc.THAR	0%new
3	Cycurion Inc.CYCU	0%0
4	BSLK - Bolt Projects Holdings, Inc.	——
5	GBIO - Generation Bio Co.	——
6	BioXcel Therapeutics, Inc.BTAI	0%new
7	Immuneering Corp. Class A Common StockIMRX	0%0
8	Anavex Life Sciences CorpAVXL	0.01%+0
9	PRPH - ProPhase Labs, Inc.	——
10	RVPH - Reviva Pharmaceuticals Holdings, Inc.	——

Cognition Therapeutics, Inc.

Healthcare
Biotechnology

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for age-related degenerative diseases affecting the central nervous system and the retina. Its lead program centers on zervimesine (CT1812), an oral candidate designed to protect neuronal synapses and modulate disease-related protein interactions. The company is evaluating this candidate across multiple neuroscience and neuro-ophthalmology settings, including Alzheimer’s disease, mild cognitive impairment, dementia with Lewy bodies, and geographic atrophy associated with dry age-related macular degeneration. Cognition Therapeutics combines mechanistic research with translational and clinical development to address disorders linked to synaptic dysfunction and cellular stress. Headquartered in Purchase, New York, the company plays a specialized role in the biotech market as a developer of targeted treatments for complex neurodegenerative and retinal conditions.

Website

Location

2500 Westchester Ave.

Purchase, NY, 10577

United States

Social

What share of all stock conversation is about CGTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.01

Jun 25

$CGTX has dropped significantly, with some speculating that the market was expecting a partnership announcement, but the FDA is still in alignment.
The company's fundamentals remain intact, with the Phase 3 DLB trial essentially confirmed and the NDA path still intact, according to some analysts.
Some investors are holding onto their long positions, with one suggesting that a large ATM (Accelerated Trading Market) may be behind the drop, and another proposing that the CEO take most of her annual compensation in stock to demonstrate her confidence in the company.

Generated by AI

Sentiment

Of the messages about CGTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% new	58.33% -16.67	89.58% +0.74
Bearish	—	50% -50	41.67% +16.67	10.42% -0.74

Bullish· Apr 1

$CGTX has shown a significant 60% increase in value, making it a profitable long-term hold.
The asset's low float is expected to lead to a price explosion, with a predicted target of $1.20.
$CGTX has already shown a remarkable turnaround, with a strong possibility of breaking through the $1 mark and potentially reaching $3.

Bearish· Jun 24

The company may be diluting the stock by selling more shares, similar to a previous massive drop.
The market may be reacting to anticipation of negative news, with some expecting a possible drop despite positive news being "baked into the share price".
The company's recent price drop may be a buying opportunity, with some investors believing there's a 50/50 chance of a total loss over a long-term horizon.

Generated by AI

Topics

Of the messages about CGTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	53.09%
Technical Analysis	0%	0%	0%	39.3%
Earnings	0%	0%	0%	2.54%
Analysts	0%	0%	0%	3.33%
Controversies	0%	0%	0%	0.16%
Macro	0%	0%	0%	1.58%

Announcements· Aug 28

Cognition Therapeutics, Inc. (CGTX) has announced a $30 million registered direct offering of 14.7 million shares to two new institutional investors, including a major global investment manager.
The proceeds from the offering will be used to advance Phase 3 programs for zervimesine, a potential treatment for Alzheimer's disease.
The offering is expected to provide a bridge funding in preparation for Phase 3 trials and may also extend the company's runway through late 2026, potentially making a buyout more likely due to increased valuations.

Technical Analysis· Aug 25

$CGTX is expected to reach $5 soon, with a current price and only 73 million outstanding shares.
The stock is showing a cup and handle formation on the 5-minute chart and a beautiful stair-stepping and consolidation pattern.
$CGTX is oversold and due for a bounce, with a potential target at $3.80 and a current price near support at $3.27.

Generated by AI

Community

Of the messages about CGTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	96.15%	87.32%	72.46%
Newcomers	14.29%	3.85%	12.68%	27.54%

Regulars· Aug 22

CGTX is exhibiting strong momentum, holding VWAP and grinding higher into $2.65, with a steep uptrend that may continue as long as it holds.
The stock's price is being closely watched by regulars, with notable price points at $2.55, $3.01, and $3.70, and a support level at $2.13.
UltraShort and UltraBuyer signals have triggered sharp price movements, with UltraShorts sparking drops of up to 20% and UltraBuyers experiencing a 60% pop before the price stalled near resistance.

Newcomers· Aug 28

Newcomers are noting the significant price increase of CGTX, which has risen by 500% in 18 days.
Some newcomers are analyzing the potential for a "pop-and-hold" in CGTX, citing Phase 3 funding and a $30M deal as narrative support.
Others are looking at a possible "flush-and-reset" in CGTX, seeing the $30M offering as strengthening the company's runway for Phase 3, despite current weakness.

Generated by AI

Cognition Therapeutics

Social

Jun 25

Bullish· Apr 1

Bearish· Jun 24

Announcements· Aug 28

Technical Analysis· Aug 25

Regulars· Aug 22

Newcomers· Aug 28

Cognition Therapeutics schedules FDA meeting on DLB drug trial

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

Best Penny Stocks of 2026: Are They a Good Investment? | The Motley Fool

H.C. Wainwright reiterates Cognition stock rating, $3 target

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Also Discussed

Cognition Therapeutics, Inc.

Company Information

Location

Cognition Therapeutics schedules FDA meeting on DLB drug trial

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

Best Penny Stocks of 2026: Are They a Good Investment? | The Motley Fool

H.C. Wainwright reiterates Cognition stock rating, $3 target

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Also Discussed

Social

Jun 25

Bullish· Apr 1

Bearish· Jun 24

Announcements· Aug 28

Technical Analysis· Aug 25

Regulars· Aug 22

Newcomers· Aug 28